Most Active Stocks

COCHINSHIP
INDIGO
BSE
SCI
JUBLINGREA
GRSE
BEL
HAL
RELIANCE
MAZDOCK
CDSL
ONGC
OIL
RPOWER
BDL
JUBLPHARMA
SBIN
HDFCBANK
INFY
GESHIP

Sun Pharma Advanced Research Company Limited

Drug Manufacturers - Specialty & Generic | Healthcare

Company Overview

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company's products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson's disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer's disease. Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.

Key Information

Market Cap

54310346752

Current Price

165.28

52 Week Range

109.3 - 258.0

Previous Close

164.88

Open

164.88

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Contact Details

Address

17/B, Mahal Industrial Estate, Off Mahakali Caves Road Andheri (East), Mumbai, 400093, India

Phone

+91-22664-55645

Fax

+91-22664-55685

Website

https://www.sparc.life

Financials

Day Low

163.31

Day High

166.29

Dividend Yield

PE Ratio

Earnings Per Share

-10.42

Beta

0.41

EBITDA

-3231399936

Book Value

-6.679

EPS

Company Officers

Name Title Age Year Born
Mr. Anilkumar Raghavan Chief Executive Officer 56 1968
Mr. Anup Rathi Chief Financial Officer - -
Dr. Nitin Dharmadhikari Chief Operating Officer 62 1962
Mr. Jaydeep Issrani Senior General Manager of Business Development, Corporate Communication & Investor Relations - -
Ms. Kajal K. Damania Company Secretary & Compliance Officer - -
Ms. Shanta Gupta Chief Human Resource Officer - -
Mr. Siu-Long Yao Head Clinical Development - -
Dr. Nitin K. Damle Ph.D. Chief Innovation Officer - -
Dr. Yashoraj Zala Head of Drug Delivery Systems - -
Dr. Vikram K. Ramanathan Head of Preclinical Development - -

Company Details

Stock History

Explore More Stocks